TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39439755

Group type: EXPERIMENTAL
Intervention: Values-based behavioral activation (VBA)
Number of subjects: 21
Study: 39440042

Group type: EXPERIMENTAL
Intervention: Intensified trans-sectoral nutritional intervention for 6 months (face-to-face dietary counseling, oral nutritional supplementation, telephone-based nutrition and exercise coaching)
Number of subjects: 9
Study: 39440409

Group type: EXPERIMENTAL
Intervention: 25 μg oral solution of misoprostol
Number of subjects: 874

Group type: COMPARATOR
Intervention: 25 μg oral tablet of misoprostol
Number of subjects: 874
Study: 39440428

Group type: EXPERIMENTAL
Intervention: Left bundle-optimized therapy CRT (LOT-CRT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BVP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Left bundle branch area pacing (LBBAP)
Number of subjects: 48
Study: 39440720

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE items
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE administration and reporting recommendations
Number of subjects: 899
Study: 39440742

Group type: EXPERIMENTAL
Intervention: CRT-D with remote monitoring
Number of subjects: 335
Study: 39441133

Group type: EXPERIMENTAL
Intervention: Peer-driven intervention through interactive voice-response (PDI-IVR) system
Number of subjects: 263

Group type: COMPARATOR
Intervention: Active-control
Number of subjects: 263
Study: 39441230

Group type: EXPERIMENTAL
Intervention: High iodine levels in cooking water
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: High iodine levels in drinking water
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Higher urinary iodine concentration (UIC)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Higher 24-h urinary iodine excretion (24-h UIE)
Number of subjects: 770
Study: 39441346

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 768

Group type: COMPARATOR
Intervention: No mechanical ventilation (NV)
Number of subjects: 768
Study: 39441483

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) 4 × 8 Gy and sequential nivolumab administration until disease progression or unacceptable toxicity
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) analysis
Number of subjects: 15
Study: 39441503

Group type: EXPERIMENTAL
Intervention: Active video game condition
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control game
Number of subjects: 39
Study: 39441519

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 10-200/50 mg
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (all doses)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib (SALT score ≤ 20 responders)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Number of subjects: 718
Study: 39441580

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 39441591

Group type: EXPERIMENTAL
Intervention: Pregabalin (50-300 mg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 39441642

Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioral therapy (bCBT) combining internet-based cognitive behavioral therapy (iCBT) and face-to-face cognitive behavioral therapy (FtF CBT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Face-to-face cognitive behavioral therapy (FtF CBT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 13
Study: 39441691

Group type: EXPERIMENTAL
Intervention: EDP-938
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 39441802

Group type: EXPERIMENTAL
Intervention: hf-tRNS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 40 Hz tACS
Number of subjects: 45

Group type: COMPARATOR
Intervention: sham tCS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 39441873

Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary rehabilitation program (30 sessions over 6 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Home-based self-treatment program (muscle-stretching and active mobilization exercises for 40'/day for 6 weeks)
Number of subjects: 72
Study: 39441901

Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy
Number of subjects: 0
Study: 39442013

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W or Q4W combined with topical corticosteroids (TCS) in the maintenance primary population (MPP)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W with TCS in the maintenance escape population (MEP)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W or Q4W combined with TCS in the MPP
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg Q2W with TCS in the MEP
Number of subjects: 271
Study: 39442018

Group type: EXPERIMENTAL
Intervention: ABP 654
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab RP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transition from Ustekinumab RP to ABP 654 at week 28
Number of subjects: 0
Study: 39442326

Group type: EXPERIMENTAL
Intervention: Surgical treatment (diaphragmatic plication)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conservative treatment (clinical follow-up)
Number of subjects: 139
Study: 39442386

Group type: EXPERIMENTAL
Intervention: 100 mg Jaktinib administered orally on day 1 in mild hepatic impairment group (n=8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg Jaktinib administered orally on day 1 in moderate hepatic impairment group (n=8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100 mg Jaktinib administered orally on day 1 in normal hepatic function group (n=8)
Number of subjects: 24
Study: 39442480

Group type: EXPERIMENTAL
Intervention: Total Caries Removal (TCR)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Selective Caries Removal (SCR)
Number of subjects: 124
Study: 39442667

Group type: EXPERIMENTAL
Intervention: STAND (Motivational Interviewing-Enhanced Behavior Therapy)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 278
Study: 39442695

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention including supplementary mental health training for nurses, workshops for doctors, and lay counselling services.
Number of subjects: 4298
Study: 39442757

Group type: EXPERIMENTAL
Intervention: Test meals (3 test meals)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PLS regression model with 16 SNPs
Number of subjects: 42
Study: 39442905

Group type: EXPERIMENTAL
Intervention: Intraoperative molecular imaging (IMI) with pafolacianine
Number of subjects: 100
Study: 39442958

Group type: EXPERIMENTAL
Intervention: Intensive adjuvant treatment (arm A): four cycles of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin (n=166)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Standard treatment (arm B): four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (n=170)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Intensive adjuvant treatment (arm A)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Standard treatment (arm B)
Number of subjects: 504
Study: 39443013

Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose (FDI)
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1137
Study: 39443015

Group type: EXPERIMENTAL
Intervention: Platelet FcγRIIa (pFCG) quantification
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (aspirin, P2Y)
Number of subjects: 800
Study: 39443081

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg twice daily for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 39443151

Group type: EXPERIMENTAL
Intervention: 3D pCASL with TSE-CASPR
Number of subjects: 41

Group type: COMPARATOR
Intervention: 3D pCASL with GRASE
Number of subjects: 41
Study: 39443386

Group type: EXPERIMENTAL
Intervention: FAPI-PET/CT
Number of subjects: 232

Group type: COMPARATOR
Intervention: Prospective observational trial (NCT04571086)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Retrospective analysis
Number of subjects: 232
Study: 39443403

Group type: EXPERIMENTAL
Intervention: Isavuconazole as primary therapy
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Isavuconazole as salvage therapy
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 218
Study: 39443446

Group type: EXPERIMENTAL
Intervention: Ductal lavage with triamcinolone acetonide and antibiotics followed by observation (DL-OBS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 140
Study: 39443463

Group type: EXPERIMENTAL
Intervention: Multi-domain cognitive training (CT)
Number of subjects: 60
Study: 39443527

Group type: COMPARATOR
Intervention: LPVr (400 mg/100 mg twice daily)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: LPVr + TLM (10 mg once daily)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: LPVr + ATV (20 mg once daily)
Number of subjects: 294

Group type: COMPARATOR
Intervention: LPVr
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: LPVr + TLM
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: LPVr + ATV
Number of subjects: 294
Study: 39443659

Group type: EXPERIMENTAL
Intervention: Amiodarone (therapeutic doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No amiodarone (ineffective group)
Number of subjects: 0
Study: 39443721

Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst stimulation (aiTBS) during the acute phase (8 times daily for up to 10 days)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst stimulation (aiTBS) during the tapering phase (2 treatment days per week for 2 weeks, followed by 1 treatment day per week for 2 weeks)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst stimulation (aiTBS) during the relapse prevention phase (scheduled based on symptom re-emergence for up to 6 months)
Number of subjects: 155
Study: 39443859

Group type: EXPERIMENTAL
Intervention: Standardized neurological examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry (age ≥ 5 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscle ultrasound
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Respiratory assessments (spirometry, maximal inspiratory and expiratory pressure, sniff nasal inspiratory pressure; age ≥ 5 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DEXA-scan; age ≥ 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: X-ray of the left hand (age ≤ 17 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower extremity MRI (age ≥ 10 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometry for 8 days (age ≥ 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaires (patient report and/or parent proxy; age ≥ 2 years)
Number of subjects: 0
Study: 39443873

Group type: EXPERIMENTAL
Intervention: Combined exercise and nutrition intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study: 39443886

Group type: EXPERIMENTAL
Intervention: Baseline Shock Index (SI) ≥ 0.9
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Thoracic sensory block height > 4
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Shock Index alone
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model
Number of subjects: 335
Study: 39443891

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Living in New York metropolitan area
Number of subjects: 0
Study: 39443924

Group type: EXPERIMENTAL
Intervention: AH Plus sealer with sonic activation
Number of subjects: 72

Group type: COMPARATOR
Intervention: AH Plus sealer without sonic activation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Endosequence BC sealer with sonic activation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Endosequence BC sealer without sonic activation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sonic activation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-activation
Number of subjects: 72
Study: 39443927

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (0.3 mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Papaverine HCl 10 mg/mL (0.3 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine 1% and Papaverine HCl
Number of subjects: 20
Study: 39443954

Group type: EXPERIMENTAL
Intervention: Ivabradine (standard treatment for sepsis plus enteral ivabradine)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard treatment group (GS)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Ivabradine (GI)
Number of subjects: 172
Study: 39443965

Group type: EXPERIMENTAL
Intervention: New General Self Efficacy Scale (NGSES)
Number of subjects: 121
Study: 39443991

Group type: EXPERIMENTAL
Intervention: Prediction models including omics data (proteins and microRNAs)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Models based on demographics alone
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Blood biomarkers (surfactant protein-D, serine protease inhibitor A7, MMP-9)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Blood biomarkers (CC motif chemokine 11, vascular cell adhesion protein-1, adiponectin, carcinoembryonic antigen, MMP-9)
Number of subjects: 231
Study: 39444003

Group type: EXPERIMENTAL
Intervention: Group 1 (low tourniquet pressure, LOP + 50 mmHg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group 2 (high tourniquet pressure, LOP + 100 mmHg)
Number of subjects: 24
Study: 39444031

Group type: EXPERIMENTAL
Intervention: Web-based training program for clinical staff
Number of subjects: 1601
Study: 39444037

Group type: COMPARATOR
Intervention: AL002 (single intravenous infusion)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: AL002 (weekly intravenous injections for 4 weeks in cynomolgus monkeys)
Number of subjects: 64
Study: 39444039

Group type: EXPERIMENTAL
Intervention: Anthracycline based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High immune infiltration (CD8+ T cells and CD20+ B cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials combining chemotherapy with immune checkpoint inhibitors
Number of subjects: 0
Study: 39444044

Group type: EXPERIMENTAL
Intervention: Whole foods diet intervention (2020-2025 Dietary Guidelines for Americans adapted whole foods diet)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole foods diet intervention
Number of subjects: 20
Study: 39444052

Group type: EXPERIMENTAL
Intervention: Prasugrel monotherapy (3.75 mg/day)
Number of subjects: 2715

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) with prasugrel and aspirin
Number of subjects: 2715

Group type: EXPERIMENTAL
Intervention: No-aspirin group
Number of subjects: 2715

Group type: COMPARATOR
Intervention: DAPT group
Number of subjects: 2715
Study: 39444331

Group type: EXPERIMENTAL
Intervention: Extubation Advisor (EA) tool implementation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interviews with critical care physicians (MDs) and respiratory therapists (RTs)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Perceived benefit of EA tool use
Number of subjects: 31
Study: 39444552

Group type: EXPERIMENTAL
Intervention: Admission glucose (AG) levels
Number of subjects: 1705
Study: 39444571

Group type: EXPERIMENTAL
Intervention: Bovine milk-based infant formula with added bovine MFGM (5 g/L) for 60 days
Number of subjects: 3

Group type: COMPARATOR
Intervention: Bovine milk-based infant formula (Control) for 60 days
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mother's own human milk (HM) for 60 days
Number of subjects: 3
Study: 39444874

Group type: EXPERIMENTAL
Intervention: Preoperative blood ctDNA somatic mutation/methylation alone or combined with PET-CT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ctDNA somatic mutation/methylation profiles alone or combined with PET-CT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Preoperative negative ctDNA profiling and/or PET-CT
Number of subjects: 200
Study: 39444881

Group type: EXPERIMENTAL
Intervention: Sublobar resection for AIS and MIA diagnosed by FS
Number of subjects: 390
Study: 39444901

Group type: EXPERIMENTAL
Intervention: Remote monitoring of home NIV (T4P device, SRETT, Paris, France) for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 39445112

Group type: EXPERIMENTAL
Intervention: Salivary Interleukin-1
Number of subjects: 0
Study: 39445319

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at baseline, Week 4, and every 12 weeks thereafter to Week 52, with final assessment at Week 64.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Tildrakizumab treatment
Number of subjects: 55
Study: 39445322

Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5%
Number of subjects: 733

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5% (subjects <65)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Vehicle (subjects <65)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5% (subjects ≥65)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Vehicle (subjects ≥65)
Number of subjects: 733
Study: 39445416

Group type: EXPERIMENTAL
Intervention: DK crush
Number of subjects: 202

Group type: COMPARATOR
Intervention: DK culotte
Number of subjects: 202
Study: 39445439

Group type: EXPERIMENTAL
Intervention: cfDNA neomer profiling at TP1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: cfDNA neomer profiling at TP2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: cfDNA neomer profiling at TP3
Number of subjects: 44

Group type: COMPARATOR
Intervention: ctDNA mutation-based results at TP1
Number of subjects: 44

Group type: COMPARATOR
Intervention: ctDNA mutation-based results at TP3
Number of subjects: 44

Group type: COMPARATOR
Intervention: ctDNA mutation-based method at TP1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: combination results
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: combination of neomer and ctDNA mutation-based results
Number of subjects: 44
Study: 39445512

Group type: EXPERIMENTAL
Intervention: Microdebrider surgical intervention (86% of children, 49% of adults)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Lasers (CO2 laser)
Number of subjects: 304
Study: 39445570

Group type: EXPERIMENTAL
Intervention: Cervical ripening with a double balloon device for 6 hours
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cervical ripening with a double balloon device for 12 hours
Number of subjects: 67
Study: 39445609

Group type: EXPERIMENTAL
Intervention: perindopril/amlodipine 4/5 mg
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: perindopril/amlodipine/indapamide 4/5/1.25 mg
Number of subjects: 440
Study: 39445704

Group type: EXPERIMENTAL
Intervention: NTLA-2002 25 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NTLA-2002 50 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 39445764

Group type: EXPERIMENTAL
Intervention: PVC burden >5%
Number of subjects: 6529

Group type: EXPERIMENTAL
Intervention: PVC burden >10%
Number of subjects: 6529

Group type: EXPERIMENTAL
Intervention: PVC burden 5.1%-10%
Number of subjects: 6529

Group type: EXPERIMENTAL
Intervention: PVC >5%
Number of subjects: 6529

Group type: EXPERIMENTAL
Intervention: PVC >5% and LVEF <50%
Number of subjects: 6529

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 6529
Study: 39445776

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Baricitinib 4 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Unanchored population-adjusted ITC
Number of subjects: 4
Study: 39445810

Group type: EXPERIMENTAL
Intervention: Co-creation workshops and in-depth interviews with healthcare providers
Number of subjects: 0
Study: 39445855

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39445920

Group type: EXPERIMENTAL
Intervention: Physical health problems at 3 months (n = 3368)
Number of subjects: 4092

Group type: EXPERIMENTAL
Intervention: Cognitive health problems at 3 months (n = 3368)
Number of subjects: 4092

Group type: EXPERIMENTAL
Intervention: Mental health problems at 3 months (n = 3368)
Number of subjects: 4092

Group type: EXPERIMENTAL
Intervention: Physical health problems at 12 months (n = 2950)
Number of subjects: 4092

Group type: EXPERIMENTAL
Intervention: Cognitive health problems at 12 months (n = 2950)
Number of subjects: 4092

Group type: EXPERIMENTAL
Intervention: Mental health problems at 12 months (n = 2950)
Number of subjects: 4092
Study: 39446087

Group type: EXPERIMENTAL
Intervention: UGN-102 (mitomycin), 6 weekly intravesical instillations
Number of subjects: 240
Study: 39446325

Group type: EXPERIMENTAL
Intervention: Simultaneous RZV and aIIV4
Number of subjects: 267

Group type: COMPARATOR
Intervention: Simultaneous RZV and HD-IIV4
Number of subjects: 267
Study: 39446327

Group type: EXPERIMENTAL
Intervention: RT twice daily to a dosage of 45 Gy for 3 weeks
Number of subjects: 638

Group type: COMPARATOR
Intervention: RT once daily to a dosage of 70 Gy for 7 weeks
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: N2 disease
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: N3 disease
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Stage IIIA cancer
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Stage IIIB cancer
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Low-volume accrual centers
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Middle-volume accrual centers
Number of subjects: 638
Study: 39446365

Group type: EXPERIMENTAL
Intervention: Intravenous nivolumab, 3 mg/kg, every 2 weeks and ipilimumab, 1 mg/kg, every 6 weeks until disease progression, intolerable adverse events, or a maximum duration of 2 years.
Number of subjects: 49